AstraZeneca vaccine booster works against Omicron, Oxford lab study finds


FILE PHOTO: People pose with syringe with needle in front of displayed AstraZeneca logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) - A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.

Findings from the study, yet to be published in a peer-reviewed medical journal, match those from rivals Pfizer-BioNTech and Moderna which have also found a third dose of their shots works against Omicron.

The study on AstraZeneca's vaccine, Vaxzevria, showed that after a three-dose course of the vaccine, neutralising levels against Omicron were broadly similar to those against the virus's Delta variant after two doses.

The London-listed company said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine with AstraZeneca.

"As we better understand Omicron, we believe we will find that T-cell response provides durable protection against severe disease and hospitalisations," Mene Pangalos, the head of AstraZeneca's biopharmaceuticals R&D said, referring to a critical component of the immune system that respond to fight infection.

Antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19, the Anglo-Swedish drugmaker added.

Although the early data is positive for the company, AstraZeneca said on Tuesday it was working with its partner Oxford University to produce a vaccine tailored for Omicron, joining similar efforts from other vaccine-makers.

The Oxford study analysed blood samples from those infected with COVID-19, those vaccinated with two doses and a booster, and those previously infected with other variants of concern. It included samples from 41 people given three doses of Vaxzevria.

Scientists and governments are scrambling to bolster defences against Omicron with shots and therapies, as the variant threatens to become dominant globally and has prompted renewed curbs ahead of the holidays to contain infections.

Britain earlier this month backed the use of boosters after it found that a third dose significantly restored protection against mild disease caused by Omicron, in part reversing an otherwise steep drop in vaccine effectiveness.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta, John Stonestreet and Elaine Hardcastle)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In World

EU to make breaking sanctions against Russia a crime, seizing assets easier
UK report blames "senior leadership" over illegal Downing Street COVID parties
Boeing Starliner capsule nears completion of pivotal test flight to orbit
EU cracks widen over Ukraine as Italy, Hungary urge truce
Venezuela opposes Norway as facilitator for political talks with opposition
Leadership to blame for illegal parties at UK Johnson's office
Apple spent millions, but it couldn’t pull these San Jose residents out of homelessness
Moldova must not lose 'historic' chance to join EU, says PM
75 people missing, one dead, after migrant boat sinks off Tunisia
Russia pushed closer to brink of default after U.S. payment license expires

Others Also Read